Regulatory body approves Trinity's purchase of Clarel (Dia)
MADRID, 14 Mar. (EUROPA PRESS) -
The National Markets and Competition Commission (CNMC) approved seven concentration operations last February, all in the first phase and one of them with commitments, including the acquisition of 20% of Grifols' stake in Shanghai RAAS Blood by Haier.
Specifically, the Spanish firm will give 20% of SRASS to Haier for around 1.8 billion US dollars (almost 1.63 billion euros). SRASS is a company listed on the Shanghai Stock Exchange, dedicated to the manufacture of blood products in China and which has its subsidiary Grifols Diagnostics Systems (Gds) in Spain.
The CNMC considers that the operation does not pose a threat to effective competition in the markets, since it does not give rise to horizontal or vertical overlaps in Spain.
In addition to this transaction, the CNMC has also approved the acquisition of exclusive control of Beauty By Dia (Clarel) by the Colombian business group Trinity. This operation will have a final price of 42.2 million euros.
Beauty By Dia, active in the retail distribution sector of perfumery, personal care and drugstore products in Spain, with its own brand and manufacturer brand products, is present in the market both through its own stores and stores in franchise regime.
According to the CNMC, the operation will not alter the competitive structure of the affected market since there are no horizontal or vertical overlaps between activities carried out by the acquirer and the acquired party. Thus, it cannot be expected to pose a threat to effective competition.
Likewise, the Japanese listed company Sintokogio has received the green light for exclusive control of the French industrial group of companies Winoa. The operation generates horizontal overlaps in the metal abrasives market.
The operation does not give rise to vertical overlaps or portfolio effects, and there are no extraordinary barriers to entry into the market. The operation barely alters the structure of the market in Spain and cannot be expected to pose a threat to competition.
For its part, Comitans has been authorized to acquire exclusive control of Rheinmetall Automotive's small bore piston business. The acquired business is concentrated in two newly created companies, Kolbenschmidt Pistons Germany GMBH and Kolbenschmidt Pistons Usa Holding LLC, which concentrate Rheinmetall's activity in the field of manufacturing, sales and distribution of small bore pistons.
Another of the operations approved in February was the exclusive purchase of Eléctrica de Moscoso and Moscoso Energía by the EHR Group. The participation of the parties to the operation in these markets is of little importance, which is why the CNMC considers that the operation does not pose a threat to effective competition.
Meanwhile, the private equity manager Portobello, which controls several venture capital funds, acquired joint control of Plexus Technologies in February. The concentration does not pose a threat to effective competition, since the overlaps between the activities of the parties in the affected markets are not significant. Therefore, the operation will not produce changes in the structure or competitive dynamics of the market.
Finally, Boston Scientific Corporation has acquired therapeutic assets from the B. Braun Group. This has been the only operation authorized by the CNMC with commitments.
